End-of-day quote
Shenzhen S.E.
18:00:00 2024-05-09 EDT
|
5-day change
|
1st Jan Change
|
8.08
CNY
|
-3.23%
|
|
+5.62%
|
-23.70%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
4,750
|
4,362
|
7,109
|
6,353
|
5,770
|
5,101
|
Enterprise Value (EV)
1 |
3,392
|
3,084
|
5,929
|
5,057
|
4,649
|
3,927
|
P/E ratio
|
16.6
x
|
29.1
x
|
46.1
x
|
15.7
x
|
27.9
x
|
50.4
x
|
Yield
|
1.22%
|
0.69%
|
0.44%
|
1.27%
|
0.72%
|
0.21%
|
Capitalization / Revenue
|
3.33
x
|
3.66
x
|
6.5
x
|
6.05
x
|
7.86
x
|
10.7
x
|
EV / Revenue
|
2.38
x
|
2.59
x
|
5.42
x
|
4.81
x
|
6.33
x
|
8.24
x
|
EV / EBITDA
|
11
x
|
19.5
x
|
37
x
|
33.5
x
|
65.5
x
|
457
x
|
EV / FCF
|
-29.1
x
|
-175
x
|
60.3
x
|
54.7
x
|
104
x
|
-118
x
|
FCF Yield
|
-3.43%
|
-0.57%
|
1.66%
|
1.83%
|
0.96%
|
-0.84%
|
Price to Book
|
1.86
x
|
1.63
x
|
2.54
x
|
1.96
x
|
1.71
x
|
1.48
x
|
Nbr of stocks (in thousands)
|
484,166
|
484,166
|
481,666
|
481,666
|
481,666
|
481,666
|
Reference price
2 |
9.810
|
9.010
|
14.76
|
13.19
|
11.98
|
10.59
|
Announcement Date
|
19-03-27
|
20-04-15
|
21-03-29
|
22-03-30
|
23-03-29
|
24-04-09
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,428
|
1,191
|
1,094
|
1,051
|
734.5
|
476.6
|
EBITDA
1 |
307.5
|
158.2
|
160.4
|
150.9
|
70.95
|
8.601
|
EBIT
1 |
284.8
|
132.5
|
123.6
|
95.41
|
24.24
|
-39.75
|
Operating Margin
|
19.95%
|
11.13%
|
11.29%
|
9.08%
|
3.3%
|
-8.34%
|
Earnings before Tax (EBT)
1 |
330.6
|
172.7
|
179.3
|
439
|
254.6
|
122.2
|
Net income
1 |
283.1
|
148.6
|
154.9
|
402.3
|
204.7
|
102.9
|
Net margin
|
19.83%
|
12.48%
|
14.16%
|
38.28%
|
27.87%
|
21.6%
|
EPS
2 |
0.5900
|
0.3100
|
0.3200
|
0.8400
|
0.4300
|
0.2100
|
Free Cash Flow
1 |
-116.4
|
-17.67
|
98.25
|
92.42
|
44.63
|
-33.15
|
FCF margin
|
-8.15%
|
-1.48%
|
8.98%
|
8.8%
|
6.08%
|
-6.96%
|
FCF Conversion (EBITDA)
|
-
|
-
|
61.25%
|
61.23%
|
62.91%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
63.42%
|
22.97%
|
21.8%
|
-
|
Dividend per Share
2 |
0.1200
|
0.0620
|
0.0650
|
0.1680
|
0.0860
|
0.0220
|
Announcement Date
|
19-03-27
|
20-04-15
|
21-03-29
|
22-03-30
|
23-03-29
|
24-04-09
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,358
|
1,278
|
1,180
|
1,296
|
1,122
|
1,174
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-116
|
-17.7
|
98.2
|
92.4
|
44.6
|
-33.1
|
ROE (net income / shareholders' equity)
|
11.6%
|
5.6%
|
5.44%
|
12.9%
|
6.05%
|
2.8%
|
ROA (Net income/ Total Assets)
|
6.83%
|
2.98%
|
2.67%
|
1.87%
|
0.43%
|
-0.69%
|
Assets
1 |
4,146
|
4,995
|
5,813
|
21,564
|
47,098
|
-14,896
|
Book Value Per Share
2 |
5.280
|
5.520
|
5.820
|
6.740
|
7.000
|
7.130
|
Cash Flow per Share
2 |
1.180
|
1.630
|
1.400
|
0.3400
|
0.4700
|
0.2500
|
Capex
1 |
198
|
111
|
118
|
45.9
|
43.3
|
52.9
|
Capex / Sales
|
13.87%
|
9.36%
|
10.77%
|
4.37%
|
5.89%
|
11.1%
|
Announcement Date
|
19-03-27
|
20-04-15
|
21-03-29
|
22-03-30
|
23-03-29
|
24-04-09
|
|
1st Jan change
|
Capi.
|
---|
| -23.70% | 539M | | +30.38% | 684B | | +26.51% | 568B | | -4.36% | 361B | | +19.30% | 329B | | +3.73% | 284B | | +16.70% | 240B | | +8.78% | 208B | | -7.93% | 200B | | +7.68% | 166B |
Other Pharmaceuticals
|